Big biotech, Big pharma, Partnering

Amgen and MD Anderson in bispecific T cell engager (BiTE) antibody pact

Posted on 14 January 2015

Tags: , ,

Amgen and The University of Texas MD Anderson Cancer Center announced a research collaborative agreement focusing on Amgen's bispecific T cell engager (BiTE) antibody constructs, an immunotherapy that serves as a "bridge" between T cells and cancer cells.

The research agreement will identify targets for this therapy in myelodysplastic syndrome (MDS), a bone marrow disorder in which the body does not produce sufficient healthy blood cells.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

 

MDS affects primarily older adults over age 60 and can cause severe anemia, potentially leading to development of acute myelogenous leukemia (AML), a blood cell cancer.

The collaboration's innovative approach will draw on the expertise of MD Anderson's Moon Shots Program, which aims to accelerate the conversion of scientific discoveries into clinical advances and significantly reduce cancer deaths. Garcia-Manero leads the MDS/AML Moon Shots Program.

The collaborative agreement will allow Amgen and MD Anderson to join forces in a research partnership that aims to take new drug development from "A to Z."

The agreement provides for joint development of new agents under pre-determined terms.

Amgen retains all commercial rights, while MD Anderson is eligible to receive milestones and royalties upon successful achievement of key objectives.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2014

View: Top pharmaceutical companies

View: Top biotech companies

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Top 50 Big Biotech Partnering and M&A Deal Trends

Print Friendly, PDF & Email

Leave a Reply